Evidence map›Paper›PMID 39185170›Full record

ArticlebioRxiv : the preprint server for biology2024

Quantitative 3D histochemistry reveals region-specific amyloid-β reduction by the antidiabetic drug netoglitazone.

Francesca Catto, Ehsan Dadgar-Kiani, Daniel Kirschenbaum, Athena Economides, Anna Maria Reuss, Chiara Trevisan, Davide Caredio, Delic Mirzet, Lukas Frick, Ulrike Weber-Stadlbauer and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Francesca CattoInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.ORCID 0000-0002-0429-2552
Ehsan Dadgar-KianiInstitute of Veterinary Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 260, 8057 Zürich.
Daniel KirschenbaumInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.
Athena EconomidesInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.ORCID 0000-0003-2340-6364
Anna Maria ReussInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.ORCID 0000-0003-1096-3030
Chiara TrevisanInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.ORCID 0000-0002-3997-094X
Davide CaredioInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.ORCID 0000-0002-3723-894X
Delic MirzetInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.
Lukas FrickInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.
Ulrike Weber-StadlbauerInstitute of Veterinary Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 260, 8057 Zürich.
Sergey LitvinovComputational Science and Engineering Laboratory, ETH Zürich, Clausiusstrasse 33, 8092, Zurich, Switzerland.
Petros KoumoutsakosComputational Science and Engineering Laboratory, Harvard University, Cambridge, MA 02138, United States.
Jin Hyung LeeDepartment of Neurology and Neurological Sciences, Stanford University, CA 94305, USA.
Adriano AguzziInstitute of Neuropathology, University Hospital Zurich, University of Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.ORCID 0000-0002-0344-6708

Funding

From Optogenetic Functional MRI to Mechanogenetic Functional UltrasoundDP1NS116783 · NINDS · STANFORD UNIVERSITY · PI LEE, JIN HYUNG · 2019 to 2024
$5.5M
Innovating high-resolution novel imaging approaches to elucidate mechanisms of prion-like spreadingof neurodegenerative diseaseR01AG064051 · NIA · STANFORD UNIVERSITY · PI GITLER, AARON D., LEE, JIN HYUNG · 2020 to 2024
$3.0M
CRCNS: US-France-Israel Research Proposal: A personalized approach to brain stimulationR01EB030884 · NIBIB · STANFORD UNIVERSITY · PI LEE, JIN HYUNG · 2020 to 2024
$1.4M
NIA NIH HHS R01 AG064051NIBIB NIH HHS R01 EB030884NINDS NIH HHS DP1 NS116783
6 · The paper itself

Abstract

A hallmark of Alzheimer's disease (AD) is the extracellular aggregation of toxic amyloid-beta (Aβ) peptides in form of plaques. Here, we identify netoglitazone, an antidiabetic compound previously tested in humans, as an Aβ aggregation antagonist. Netoglitazone improved cognition and reduced microglia activity in a mouse model of AD. Using quantitative whole-brain three-dimensional histology (Q3D), we precisely identified brain regions where netoglitazone reduced the number and size of Aβ plaques. We demonstrate the utility of Q3D in preclinical drug evaluation for AD by providing a high-resolution brain-wide view of drug efficacy. Applying Q3D has the potential to improve pre-clinical drug evaluation by providing information that can help identify mechanisms leading to brain region-specific drug efficacy.

Indexed as

Alzheimer’s diseaseamyloid beta aggregatesamyloid plaquesmicroglianetoglitazoneneuroinflammationperoxisome proliferators activated receptor-gamma

Identifiers

PMID39185170
PMCPMC11343181

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.